fustls is a co-activator of androgen receptor in prostate cancer cellsfustls co-activator的雄激素受体在前列腺癌细胞.pdfVIP

FUS/TLS Is a Co-Activator of Androgen Receptor in Prostate Cancer Cells Simon Haile, Aaron Lal, Jae-Kyung Myung, Marianne D. Sadar* Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada Abstract Androgen receptor (AR) is a member of the nuclear receptor family of transcription factors. Upon binding to androgens, AR becomes transcriptionally active to regulate the expression of target genes that harbor androgen response elements (AREs) in their promoters and/or enhancers. AR is essential for the growth and survival of prostate cancer cells and is therefore a target for current and next-generation therapeutic modalities against prostate cancer. Pathophysiologically relevant protein-protein interaction networks involving AR are, however, poorly understood. In this study, we identified the protein FUsed/Translocated in LipoSarcoma (FUS/TLS) as an AR-interacting protein by co-immunoprecipitation of endogenous proteins in LNCaP human prostate cancer cells. The hormonal response of FUS expression in LNCaP cells was shown to resemble that of other AR co-activators. FUS displayed a strong intrinsic transactivation capacity in prostate cancer cells when tethered to basal promoters using the GAL4 system. Chromatin immunoprecipitation experiments showed that FUS was recruited to ARE III of the enhancer region of the PSA gene. Data from ectopic overexpression and ‘‘knock-down’’ approaches demonstrated that AR transcriptional activity was enhanced by FUS. Depletion of FUS reduced androgen- dependent proliferation of LNCaP cells. Thus, FUS is a novel co-activator of AR in prostate cancer cells. Citation: Haile S, Lal A, Myung J-K, Sadar MD (2011) FUS/TLS Is a Co-Activator of Androgen Receptor in Prostate Cancer Cells. PLoS ONE 6(9): e24197. doi:10.1371/ journal.pone.0024197 Editor: Nat